Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia

Olga Yu Fedorenko, Anton J.M. Loonen, Natalya M. Vyalova, Аnastasiya S. Boiko, Ivan V. Pozhidaev, Diana Z. Osmanova, Lyubov D. Rakhmazova, Nikolay Bokhan, Mikhail V. Ivanov, Maxim B. Freidin, Svetlana Ivanova

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychoticinduced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia.

Original languageEnglish
Pages (from-to)25-33
Number of pages9
JournalPhysiology and Pharmacology
Volume21
Issue number1
Publication statusPublished - 1 Jan 2017

Fingerprint

Cytochrome P-450 CYP2D6
Hyperprolactinemia
schizophrenia
Schizophrenia
Antipsychotic Agents
Genes
Single Nucleotide Polymorphism
genetic test
Receptor, Serotonin, 5-HT2C
Paranoid Schizophrenia
heredity
Polymorphism
Gene
Pharmacogenetics
Computer Systems
Dopamine Receptors
Cytochromes
Prolactin
medication
Real-Time Polymerase Chain Reaction

Keywords

  • Antipsychotics
  • Gene polymorphism
  • Hyperprolactinemia
  • Schizophrenia

ASJC Scopus subject areas

  • Physiology
  • Language and Linguistics
  • Pharmacology
  • Linguistics and Language

Cite this

Fedorenko, O. Y., Loonen, A. J. M., Vyalova, N. M., Boiko, А. S., Pozhidaev, I. V., Osmanova, D. Z., ... Ivanova, S. (2017). Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiology and Pharmacology, 21(1), 25-33.

Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. / Fedorenko, Olga Yu; Loonen, Anton J.M.; Vyalova, Natalya M.; Boiko, Аnastasiya S.; Pozhidaev, Ivan V.; Osmanova, Diana Z.; Rakhmazova, Lyubov D.; Bokhan, Nikolay; Ivanov, Mikhail V.; Freidin, Maxim B.; Ivanova, Svetlana.

In: Physiology and Pharmacology, Vol. 21, No. 1, 01.01.2017, p. 25-33.

Research output: Contribution to journalArticle

Fedorenko, OY, Loonen, AJM, Vyalova, NM, Boiko, АS, Pozhidaev, IV, Osmanova, DZ, Rakhmazova, LD, Bokhan, N, Ivanov, MV, Freidin, MB & Ivanova, S 2017, 'Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia', Physiology and Pharmacology, vol. 21, no. 1, pp. 25-33.
Fedorenko OY, Loonen AJM, Vyalova NM, Boiko АS, Pozhidaev IV, Osmanova DZ et al. Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiology and Pharmacology. 2017 Jan 1;21(1):25-33.
Fedorenko, Olga Yu ; Loonen, Anton J.M. ; Vyalova, Natalya M. ; Boiko, Аnastasiya S. ; Pozhidaev, Ivan V. ; Osmanova, Diana Z. ; Rakhmazova, Lyubov D. ; Bokhan, Nikolay ; Ivanov, Mikhail V. ; Freidin, Maxim B. ; Ivanova, Svetlana. / Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. In: Physiology and Pharmacology. 2017 ; Vol. 21, No. 1. pp. 25-33.
@article{3de7e6b09cde4110ad4d8d3d14a2630a,
title = "Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia",
abstract = "Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan{\circledR} SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychoticinduced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia.",
keywords = "Antipsychotics, Gene polymorphism, Hyperprolactinemia, Schizophrenia",
author = "Fedorenko, {Olga Yu} and Loonen, {Anton J.M.} and Vyalova, {Natalya M.} and Boiko, {Аnastasiya S.} and Pozhidaev, {Ivan V.} and Osmanova, {Diana Z.} and Rakhmazova, {Lyubov D.} and Nikolay Bokhan and Ivanov, {Mikhail V.} and Freidin, {Maxim B.} and Svetlana Ivanova",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "21",
pages = "25--33",
journal = "Physiology and Pharmacology",
issn = "1735-0581",
publisher = "Neuroscience Research Center",
number = "1",

}

TY - JOUR

T1 - Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia

AU - Fedorenko, Olga Yu

AU - Loonen, Anton J.M.

AU - Vyalova, Natalya M.

AU - Boiko, Аnastasiya S.

AU - Pozhidaev, Ivan V.

AU - Osmanova, Diana Z.

AU - Rakhmazova, Lyubov D.

AU - Bokhan, Nikolay

AU - Ivanov, Mikhail V.

AU - Freidin, Maxim B.

AU - Ivanova, Svetlana

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychoticinduced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia.

AB - Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychoticinduced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia.

KW - Antipsychotics

KW - Gene polymorphism

KW - Hyperprolactinemia

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85018814645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018814645&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 25

EP - 33

JO - Physiology and Pharmacology

JF - Physiology and Pharmacology

SN - 1735-0581

IS - 1

ER -